NASDAQ · Drug Manufacturers - Specialty & Generic

ESPR (ESPR) Stock

$3.18 +0.00% NASDAQ: ESPR Healthcare

Valuation

MetricValue
Price$3.18
Market Cap$661.15M
P/E Ratio-131.40
P/B Ratio-2.60
P/S Ratio1.58
EPS (TTM)$-0.11
52-Week High$4.18
52-Week Low$1.10
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE1.99%
ROA-1.60%
ROCE46.73%
Gross Margin14.89%
Operating Margin14.89%
Net Margin-1.77%
Debt/Equity-1.77
Current Ratio0.56

Annual Financials (USD)

Metric20212022202320242025
Revenue$78.0M$75.0M$116.0M$332.0M$403.0M
Operating Profit$-227.0M$-180.0M$-156.0M$54.0M$60.0M
Net Profit$-269.0M$-234.0M$-209.0M$-52.0M$-23.0M
EPS$-11.03$-4.33$-2.03$-0.28$-0.11
Op Margin-289.0%-237.8%-133.7%16.4%14.9%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$382.0M$248.0M$206.0M$344.0M$466.0M
Total Liabilities$579.0M$572.0M$661.0M$733.0M$768.0M
Cash$209.0M$125.0M$82.0M$145.0M$168.0M
Borrowings$260.0M$261.0M$541.0M$591.0M$548.0M

Latest News

Esperion Therapeutics Clears Key Hurdle as Stockholders Approve Essence Merger MarketBeat · Jul 10, 2026 Esperion Therapeutics (ESPR) Stock Fair Value Moves Lower After Analyst Downgrades Simply Wall St. · Jun 23, 2026 Why Is Altimmune (ALT) Down 11.3% Since Last Earnings Report? Zacks · Jun 12, 2026 Catalyst (CPRX) Up 0.6% Since Last Earnings Report: Can It Continue? Zacks · Jun 10, 2026 Esperion Presents New Data from CLEAR Outcomes and the CLEAR PATH Phase 2 Pediatric Study at the European Atherosclerosis Society Congress 2026 GlobeNewswire · May 26, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-264.0M$-175.0M$-135.0M$-24.0M$-13.0M
Investing Cash Flow$-50.0M$8.0M$43.0M$-1.0M$0
Financing Cash Flow$50.0M$0$-6.0M$-40.0M$-7.0M
Net Cash Flow$-46.0M$-134.0M$-43.0M$63.0M$23.0M
Free Cash Flow$-264.0M$-175.0M$-135.0M$-24.0M$-13.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.40
EV / EBITDA26.29
FCF Yield-2.75%
Quick Ratio1.18
Interest Coverage1.67
Return 1Y169.49%
Return 3Y120.83%
Return 5Y-82.01%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AGIO $31.72 +0.38% -3.56 $1.89B 0.00%
COLL $35.58 +0.54% 17.33 $1.15B 0.00%
EBS $7.16 -1.45% 8.67 $369.17M 0.00%
HRTX $0.51 +3.06% -7.08 $96.80M 0.00%
KPTIKaryopharm Therapeutics Inc. $7.60 +2.56% -0.50 $172.24M 0.00%

About ESPR

ESPR is led by CEO Sheldon L. Koenig, employs 304 people, headquartered in US, publicly traded since 2013.

ESPR stock trades at $3.18 with a market capitalization of $661.15M. The stock is valued at a price-to-earnings (P/E) ratio of -131.40, price-to-book of -2.60, price-to-sales of 1.58. Over the past 52 weeks the stock has ranged between $1.10 and $4.18, and currently trades 23.9% below its 52-week high.

On profitability, ESPR generates a return on equity (ROE) of 1.99%, return on capital employed of 46.73%, an operating margin of 14.89%, a net profit margin of -1.77%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides